Characteristics and outcomes of patients with HCC treated with atezolizumab/bevacizumab, stratified by second line therapy
1L Atezo+bev was clinically active with 256 patients remaining on therapy at last follow-up. Patients who progressed after 1L atezo+bev benefited from additional systemic therapies. Future research analyzing the comparative effectiveness of 2L therapies is needed.
Authors
- Prathamesh Pathak (ORCID: https://orcid.org/0009-0003-6107-4185)
- F. Pisa
- Zdravko P. Vassilev (ORCID: https://orcid.org/0000-0002-4902-6784)
- Sarah W. Gordon (ORCID: https://orcid.org/0000-0003-0443-5573)
- Kirhan Özgürdal (ORCID: https://orcid.org/0000-0003-3812-0692)
- William S. John
- Xiaoyun Pan (ORCID: https://orcid.org/0000-0003-2844-4044)
- Taavy A. Miller
- Amit G. Singal
- Bruce Feinberg
Institutions
- Bayer (United States) (US)
- Cardinal Health (United States) (US)
- Southwestern Medical Center (US)
- Bayer (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1080/14796694.2026.2614306
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00